'Competition intensity in diagnostics moderating'

In the first half of 2023-24, the company's core revenue, excluding Covid-19 and allied tests and government contracts, grew 13%. The volume growth is higher than the pre-pandemic level of 9%, signifying some stability to the sector. The EBITDA margin in the first half of this fiscal stood at 24.7%. The company expects the EBITDA margin would be 26-27% for the next few quarters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/scrNwz9
via IFTTT